Overview
Metastatic malignant neoplasms involving the cervix uteri represent a significant clinical challenge, particularly in low- and middle-income countries (LMICs). These patients often face substantial symptom burden, including vaginal bleeding, pelvic pain, and psychological distress, which can severely impact their quality of life (QoL). Awareness of palliative care (PC) among patients and healthcare providers varies widely, with many patients lacking access to essential supportive services. For instance, in a study involving patients from diverse backgrounds, only 63% had heard of palliative care, primarily through cancer care settings and word-of-mouth recommendations [PMID:32976942]. This highlights a critical gap in education and awareness that needs to be addressed to improve patient outcomes. In regions like South Africa and Zimbabwe, where cervical cancer constitutes a substantial portion of cancer diagnoses, the mortality rates underscore the urgent need for integrated palliative care approaches to manage symptoms and enhance overall well-being [PMID:37726748], [PMID:32054480].
Epidemiology
Cervical cancer remains a significant public health issue globally, particularly in LMICs, where it constitutes a notable percentage of all cancer diagnoses. In South Africa, cervical cancer accounts for approximately 15.85% of all histologically diagnosed cancers, with an alarming mortality rate of 19.6 per 100,000 population [PMID:37726748]. This high mortality rate reflects the advanced stages at which many cases are diagnosed, often due to limited access to early screening and treatment. Similarly, in Zimbabwe, cervical cancer presents a substantial burden, with over 1,300 new cases reported annually, and approximately 80% of these cases diagnosed at late stages due to inadequate healthcare infrastructure and delayed diagnosis [PMID:32054480]. These statistics highlight the critical need for enhanced palliative care strategies, especially in regions where curative treatments are often ineffective due to late-stage presentation.
Disparities in palliative care access further exacerbate the challenges faced by minority populations. Studies indicate that racial and ethnic minorities are disproportionately underrepresented in palliative care consultations, with only 17.5% of cervical cancer patients receiving such consultations [PMID:40265277]. This disparity is compounded by socioeconomic factors, as evidenced by the finding that Medicaid insurance coverage and younger age at diagnosis correlate with higher utilization of palliative care services [PMID:40265277]. These disparities underscore the necessity for targeted interventions to ensure equitable access to palliative care across diverse populations.
Diagnosis
Diagnosing metastatic malignant neoplasms in the cervix uteri typically involves a combination of clinical examination, imaging studies, and histopathological confirmation. Common presenting symptoms include vaginal bleeding, pelvic pain, and abnormal vaginal discharge, which are frequently observed in over two-thirds of patients [PMID:17998655]. Advanced imaging techniques such as CT scans and MRI can help delineate the extent of metastatic spread, particularly to regional lymph nodes and distant organs. However, in resource-limited settings, these diagnostic tools may be scarce, leading to delayed or inaccurate staging. Early detection remains challenging, with only 19% of women diagnosed with cervical cancer receiving appropriate treatment, highlighting systemic barriers in healthcare access [PMID:31357977].
Given the advanced stages at which many cases are diagnosed, palliative care often becomes the primary management approach, focusing on symptom control and quality of life improvement rather than curative intent. The clinical presentation often includes not only physical symptoms but also significant psychological distress, including anxiety and depression, which are prevalent among patients in LMICs [PMID:37726748]. Comprehensive assessment by a multidisciplinary team, including palliative care specialists, can help address these multifaceted issues effectively.
Clinical Presentation
Patients with metastatic cervical cancer frequently experience a constellation of distressing symptoms that significantly impact their quality of life. Common symptoms include vaginal bleeding, which affects approximately 67% of patients, followed by vaginal discharge (69%) and pelvic pain (48%) [PMID:17998655]. These symptoms not only cause physical discomfort but also psychological distress, often manifesting as anxiety and depression. Financial distress is another critical component, particularly in settings where healthcare costs are prohibitive and insurance coverage is limited. Studies have shown that palliative care consultations can lead to better symptom management, with interventions effectively controlling vaginal bleeding in 90% of cases and reducing malodorous discharge in 39% of patients [PMID:11426980]. However, the underutilization of palliative care services remains a significant barrier, with only a minority of patients receiving timely consultations, often due to late referrals and systemic barriers [PMID:40265277].
The performance status of patients with recurrent or metastatic disease is often poor, limiting their eligibility for aggressive treatments and necessitating a focus on palliative strategies. In a case series, patients with recurrent cervical cancer and poor performance status were found to benefit from targeted palliative approaches, such as low-dose apatinib and tegafur-gimeracil-oteracil, which provided meaningful disease control with manageable side effects [PMID:32737931]. These findings underscore the importance of individualized symptom management plans that address both physical and psychological needs, enhancing overall patient comfort and well-being.
Management
The management of metastatic malignant neoplasms in the cervix uteri primarily revolves around palliative care due to the advanced stage at diagnosis in many cases. Integrating palliative care early into the treatment plan has been shown to significantly enhance quality of life (QoL) and reduce symptom burden for both patients and their families [PMID:37726748]. Early integration of palliative care services, as recommended by organizations such as the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO), can mitigate psychological distress and improve overall outcomes [PMID:33276985]. However, disparities in access persist, with racial and ethnic minorities less likely to receive these services due to systemic barriers and provider biases [PMID:36762494].
Symptom Management
Symptom management is central to palliative care for these patients. Common symptoms like pelvic pain and vaginal bleeding are effectively managed through various modalities:
Multidisciplinary Care
A multidisciplinary approach is crucial for comprehensive management:
Addressing Disparities
Efforts to address disparities in palliative care access are essential:
Complications
Despite the critical role of palliative care, several complications can arise, particularly in resource-limited settings:
Prognosis & Follow-up
The prognosis for patients with metastatic cervical cancer is often guarded, with significant variability influenced by factors such as stage at diagnosis, performance status, and access to palliative care. Globally, approximately 2.6 million patients experience moderate to severe distress, with a disproportionate burden in LMICs [PMID:37726748]. Late integration of palliative care remains a common issue, with median times from diagnosis to consultation often exceeding 16 months, and only a small fraction referred within the first month [PMID:40265277]. This delay can negatively impact symptom management and overall QoL.
End-of-Life Care
End-of-life care planning is crucial:
Follow-Up Systems
Effective follow-up systems are essential to monitor symptoms and adjust care plans:
Special Populations
Minority Groups
Minority populations face unique challenges in accessing and benefiting from palliative care:
Resource-Limited Settings
Countries like Zimbabwe face significant barriers in providing adequate palliative care:
Key Recommendations
References
1 Ooko F, Mothiba T, Van Bogaert P, Wens J. Access to palliative care in patients with advanced cancer of the uterine cervix in the low- and middle-income countries: a systematic review. BMC palliative care 2023. link 2 Tabuyo-Martin A, Torres-Morales A, Pitteloud MJ, Kshetry A, Oltmann C, Pearson JM et al.. Palliative Medicine Referral and End-of-Life Interventions Among Racial and Ethnic Minority Patients With Advanced or Recurrent Gynecologic Cancer. Cancer control : journal of the Moffitt Cancer Center 2023. link 3 Islam JY, Deveaux A, Previs RA, Akinyemiju T. Racial and ethnic disparities in palliative care utilization among gynecological cancer patients. Gynecologic oncology 2021. link 4 Tapera O, Nyakabau AM. Limited knowledge and access to palliative care among women with cervical cancer: an opportunity for integrating oncology and palliative care in Zimbabwe. BMC palliative care 2020. link 5 Tapera O, Dreyer G, Kadzatsa W, Nyakabau AM, Stray-Pedersen B, Hendricks SJH. Determinants of access and utilization of cervical cancer treatment and palliative care services in Harare, Zimbabwe. BMC public health 2019. link 6 Purdy S, Lasseter G, Griffin T, Wye L. Impact of the Marie Curie Cancer Care Delivering Choice Programme in Somerset and North Somerset on place of death and hospital usage: a retrospective cohort study. BMJ supportive & palliative care 2015. link 7 Wall JA, Bratches RW, Barton WC, Boitano TKL, Li P, Tucker R et al.. Specialty Palliative Care Consultation in Patients with Cervical Cancer: Who and Why?. Journal of palliative medicine 2025. link 8 Mah SJ, Carter Ramirez DM, Eiriksson LR, Schnarr K, Gayowsky A, Seow H. Palliative care utilization across health sectors for patients with gynecologic malignancies in Ontario, Canada from 2006 to 2018. Gynecologic oncology 2023. link 9 Hicks-Courant K, Graul A, Ko E, Giuntoli R, Martin L, Morgan M et al.. Sources of Palliative Care Knowledge Among Patients With Advanced or Metastatic Gynecologic Cancer. Journal of pain and symptom management 2021. link 10 Xu XJ, Wang ZM, Shang YP, Jiang SN. Low-dose apatinib and tegafur-gimeracil-oteracil as palliative treatment in recurrent cervical cancer patients with poor performance status: A case series. Journal of clinical pharmacy and therapeutics 2020. link 11 Stoltenberg M, Spence D, Daubman BR, Greaves N, Edwards R, Bromfield B et al.. The central role of provider training in implementing resource-stratified guidelines for palliative care in low-income and middle-income countries: Lessons from the Jamaica Cancer Care and Research Institute in the Caribbean and Universidad Católica in Latin America. Cancer 2020. link 12 Cain JM, Denny L. Palliative care in women's cancer care: Global challenges and advances. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2018. link 13 Hata M, Koike I, Miyagi E, Asai-Sato M, Kaizu H, Mukai Y et al.. Radiation Therapy for Patients with Bone Metastasis from Uterine Cervical Cancer: Its Role and Optimal Radiation Regimen for Palliative Care. Anticancer research 2018. link 14 Mishra SK, Laskar S, Muckaden MA, Mohindra P, Shrivastava SK, Dinshaw KA. Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix. Journal of cancer research and therapeutics 2005. link 15 Onsrud M, Hagen B, Strickert T. 10-Gy single-fraction pelvic irradiation for palliation and life prolongation in patients with cancer of the cervix and corpus uteri. Gynecologic oncology 2001. link 16 Thigpen JT, Vance R, Puneky L, Khansur T. Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Seminars in oncology 1995. link
16 papers cited of 17 indexed.